skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All


Show More


Show More

Show More


Show More

Show More

67 Total results for product and free and sample content found

Datamonitor Healthcare, Strategic Transaction...

BCMA – Biopharma Can’t Miss Action

18 Feb 2019

It has been a busy start to the year for the hot oncology drug target B-cell maturation antigen (BCMA), after AbbVie entered the race with a $90m upfront deal for Teneobio’s preclinical bi-specific antibody TNB-383B. Acting to link T cells via the CD3 receptor with BCMA-expressing multiple myeloma cells, this is one of the most competitive new immuno-oncology approaches. The deal follows on the heels of updates to development programs of anti-BCMA candidates from Regeneron and Amgen, while bluebird/Celgene, GlaxoSmithKline, and Johnson & Johnson are among the most advanced companies in the space.

Topic Cancer Deal trends


Breast Cancer Trial Landscape Trends, 2008-2017

By Rachel Meighan-Mantha and Angela Weidner 05 Dec 2018

Female breast cancer is the second most common cancer worldwide in terms of new cases and the leading cause of cancer death in women, according to the Global Cancer Observatory

Topic Cancer Research


Geographic Trials Trends: Digging Beneath the Surface

By Laura Runkel 16 Nov 2018

The geographic scope of industry sponsored clinical trial activities has gone global. Successful programs require putting all the pieces together to ensure efficient enrollment of the target patients at high quality facilities to reliably execute detailed study protocols.  Myriad differences between countries, including disease epidemiology, standard of care options, and logistical factors around medical facilities and practices, create challenges to making the right geographic choices.

Topic Clinical trials

Skipta, Citeline

A Nautical but Nice Look at BTK inhibitors for Rheumatoid Arthritis

By Pamela Spicer 08 Oct 2018

Skipta, the leading social network of specialized online medical communities for verified healthcare professionals, recently hosted a virtual advisory board session, through its proprietary Skipta Gather technology, asking physicians what they saw as the current unmet needs in the treatment of rheumatoid arthritis (RA).

Topic Arthritis

Datamonitor Healthcare

Autologous Stem Cell Therapy for Multiple Sclerosis DeMISTified

22 Aug 2018

Phase III MIST trial data presented at the 2018 annual meeting of the American Academy of Neurology (AAN) highlight autologous hematopoietic stem cell therapy (aHSCT) as a radically novel prospect for multiple sclerosis (MS) treatment, with an unprecedented curative potential. Certainly, aHSCT’s potential to reverse disability is markedly distinct from currently available disease-modifying therapies (DMTs), which can only slow disability progression.

Trialtrove, Pharmaprojects

A Summary of 2017 Trial Initiations in NAFLD

By Ethan Hebert 13 Jul 2018

In the following, I will leverage Trialtrove and Pharmaprojects data to assess 2017 trial initiations focused on non-alcoholic fatty liver disease (NAFLD), including the subtype non-alcoholic steatohepatitis (NASH).  This analysis will include an initial wide glance at the trial landscape, focusing down to industry-sponsored trials in NASH.

Topic Diseases


Clinical Trials Activity Analysis: Factoring in Delayed Reporting

By Susan Danheiser 09 Jul 2018

The timing of when sponsors report clinical trials in the public domain continues to be a topic of interest.  Despite efforts to regulate and encourage prospective reporting of study starts, delayed reporting remains and is a factor that is often overlooked when evaluating clinical trial trends.  Here, we examine the magnitude of clinical trial reporting delays and how they can be accounted for in your analyses.

Topic Clinical trials


Revised and Newly Added Oncology Refractory/Relapsed Patient Segments in Trialtrove

By Citeline Oncology Editorial Team 15 Jun 2018

In oncology trials, patients are often differentiated based on line of therapy (LOT) for their current disease stage.  Briefly, patients can be naïve/untreated (First line), treated before or after surgery/radiation (Neoadjuvant and Adjuvant), treated after progressing on a previous line of therapy (Second line or greater) or treated to maintain a positive response (Maintenance/Consolidation).  In Trialtrove, these LOT patient segments have been applied to most oncological disease trials for almost a decade.

Topic Cancer


Type 2 Diabetes and Heart Failure - New Spotlight on an Old Problem

By Jake Mathon 08 Jun 2018

It has long been known that diabetes is a risk factor for heart failure. Analysis from the Framingham Heart Study established that men with type 2 diabetes had a 2.4-fold increase in heart failure and women had a five-fold increase. This link between the diseases is not just one way as more recent research has found the reverse to be in effect as well, that heart failure indeed is its own risk factor for diabetes mellitus.

Topic Diabetes

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: